Sugi Predict

Sugi Predict / Compounds / SCHEMBL7189022

SCHEMBL7189022

SCHEMBL7189022

CCOc1cccc(OCC)c1C(=O)c1ccccc1[P](=O)C(=O)c1c(C)cccc1C

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HCRTR1 O43613 2/20 0.40
▸ MAPT P10636 3/20 0.38
▸ CNR2 P34972 2/20 0.38
▸ TP53 P04637 1/20 0.38
▸ L3MBTL1 Q9Y468 3/20 0.38
▸ GLA P06280 1/20 0.38
▸ RAB9A P51151 2/20 0.37
▸ KCNK3 O14649 2/20 0.37
▸ KCNK9 Q9NPC2 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ NPC1 O15118 1/20 0.36
▸ GAA P10253 2/20 0.36
▸ LMNA P02545 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ NPSR1 Q6W5P4 2/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ ALOX12 P18054 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7175433 0.92 KCNK3 (0.39) HCRTR1MAPTCNR2TP53L3MBTL1
SCHEMBL7182352 0.88 KCNK3 (0.44) HCRTR1MAPTTP53L3MBTL1GLA
SCHEMBL7181297 0.88 MAPT (0.37) HCRTR1MAPTCNR2TP53L3MBTL1
SCHEMBL7181232 0.87 HCRTR1 (0.39) HCRTR1MAPTCNR2TP53L3MBTL1
SCHEMBL7182147 0.85 KCNK3 (0.48) HCRTR1L3MBTL1GLARAB9AKCNK3
SCHEMBL7732147 0.84 MAPT (0.44) HCRTR1MAPTTP53RAB9AKCNK3
SCHEMBL7188217 0.82 HPGD (0.35) MAPTCNR2KDM4EMAPK1NPSR1
SCHEMBL7177390 0.81 CA12 (0.41) MAPTRAB9AKCNK3KCNK9KDM4E
SCHEMBL7180294 0.81 ALDH1A1 (0.43) MAPTTP53L3MBTL1RAB9AKCNK3
SCHEMBL7181446 0.80 GFER (0.36) MAPTCNR2TP53RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 HCRTR1 1841/4885MAPT 4870/4885CNR2 1721/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 HCRTR1 2117/4885MAPT 4859/4885CNR2 1343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.